NCT05472649
Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy
Enrolling by Invitation
Not specifiedAll AgesObservationalSorrento Therapeutics, Inc.
~1 participants
Updated 2023-01-23 on ClinicalTrials.gov
What's tested:Gene-Modified Cell Therapy
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Long-term safety of previous treatment with gene-modified cells
Measured over Baseline through end of study (approximately 15 years)
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Mike Royal, MD · STUDY_DIRECTOR · Sorrento Therapeutics, Inc.
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Patients must have received any amount of a CGT in a study sponsored by Sorrento Therapeutics, Inc.
Exclusion
Unable or unwilling to provide written informed consent and/or comply with study requirements.
What this trial measures
- Long-term safety of previous treatment with gene-modified cellsBaseline through end of study (approximately 15 years)
Long-term safety of previous treatment as assessed by incidence of adverse events (AEs)